Mexico moves to increase regulatory efficiency, but prioritises generics
This article was originally published in SRA
Executive Summary
Mexican authorities have introduced several new measures aimed at getting more drugs to the market more quickly. However, generic medicines manufacturers are most likely to benefit, because, as Mikel Arriola, commissioner of the health protection agency, COFEPRIS, recently told local companies, such products are the government's top priority1.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.